Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes by sex following treatment initiation with darunavir/cobicistat in a large Spanish cohort of the CODAR study (GeSIDA 9316).
Pérez Elías MJ, Alejos B, Vivancos MJ, Ribera E, Galindo MJ, Vilanova-Trillo L, García-Fraile Fraile LJ, de La Fuente Moral S, Garcia De Lomas J, Lozano F, Mateo García MG, Tasias Pitarch M, Diez Martinez M, Rojas J, Raya-Cruz M, Sepúlveda MA, Troya J, Del Campo S, Martinez E. Pérez Elías MJ, et al. Among authors: rojas j. J Antimicrob Chemother. 2019 Oct 1;74(10):3124. doi: 10.1093/jac/dkz331. J Antimicrob Chemother. 2019. PMID: 31377772 No abstract available.
Outcomes by sex following treatment initiation with darunavir/cobicistat in a large Spanish cohort of the CODAR study (GeSIDA 9316).
Pérez Elías MJ, Alejos B, Vivancos MJ, Ribera E, Galindo MJ, Vilanova-Trillo L, García-Fraile Fraile LJ, de La Fuente Moral S, Garcia De Lomas J, Lozano F, Mateo García MG, Tasias Pitarch M, Diez Martinez M, Rojas J, Raya-Cruz M, Sepúlveda MA, Troya J, Del Campo S, Martinez E; CODAR study group. Pérez Elías MJ, et al. Among authors: rojas j. J Antimicrob Chemother. 2019 Oct 1;74(10):3044-3048. doi: 10.1093/jac/dkz254. J Antimicrob Chemother. 2019. PMID: 31236601
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.
Pulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-Gómez FJ, Téllez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR; DUAL-GESIDA-8014-RIS-EST45 Study Group. Pulido F, et al. Clin Infect Dis. 2017 Nov 29;65(12):2112-2118. doi: 10.1093/cid/cix734. Clin Infect Dis. 2017. PMID: 29020293 Clinical Trial.
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Inciarte A, Leal L, González E, León A, Lucero C, Mallolas J, Torres B, Laguno M, Rojas J, Martínez-Rebollar M, González-Cordón A, Cruceta A, Arnaiz JA, Gatell JM, García F; STRIBPEP Study Group. Inciarte A, et al. Among authors: rojas j. J Antimicrob Chemother. 2017 Oct 1;72(10):2857-2861. doi: 10.1093/jac/dkx246. J Antimicrob Chemother. 2017. PMID: 29091217 Clinical Trial.
Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19.
Garcia-Vidal C, Alonso R, Camon AM, Cardozo C, Albiach L, Agüero D, Marcos MA, Ambrosioni J, Bodro M, Chumbita M, de la Mora L, Garcia-Pouton N, Dueñas G, Hernandez-Meneses M, Inciarte A, Cuesta G, Meira F, Morata L, Puerta-Alcalde P, Herrera S, Tuset M, Castro P, Prieto-Gonzalez S, Almuedo-Riera A, Mensa J, Martínez JA, Sanjuan G, Nicolas JM, Del Rio A, Muñoz J, Vila J, Garcia F, Soriano A; Hospital Clinic of Barcelona COVID-19 Research Group. Garcia-Vidal C, et al. J Antimicrob Chemother. 2021 Nov 12;76(12):3296-3302. doi: 10.1093/jac/dkab321. J Antimicrob Chemother. 2021. PMID: 34473275 Free PMC article.
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
Podzamczer D, Imaz A, Perez I, Viciana P, Valencia E, Curto J, Martín T, Castaño M, Rojas J, Espinosa N, Moreno V, Asensi V, Iribarren JA, Clotet B, Force L, Bachiller P, Knobel H, López Bernaldo De Quirós JC, Blanco JR, Rozas N, Vergas J, Ocampo A, Camacho A, Flores J, Gomez-Sirvent JL; KIDAR Study Group. Podzamczer D, et al. Among authors: rojas j. J Antimicrob Chemother. 2014 Sep;69(9):2536-40. doi: 10.1093/jac/dku157. Epub 2014 May 15. J Antimicrob Chemother. 2014. PMID: 24833755
Observational cohort study of rilpivirine (RPV) utilization in Europe.
Cozzi-Lepri A, Peters L, Pelchen-Matthews A, Neesgaard B, De Wit S, Johansen IS, Edwards S, Stephan C, Adamis G, Staub T, Zagalo A, Domingo P, Elbirt D, Kusejko K, Brännström J, Paduta D, Trofimova T, Szlavik J, Zilmer K, Losso M, Van Eygen V, Pai H, Lundgren J, Mocroft A; EuroSIDA Study Group. Cozzi-Lepri A, et al. AIDS Res Ther. 2022 Aug 6;19(1):38. doi: 10.1186/s12981-022-00457-0. AIDS Res Ther. 2022. PMID: 35933352 Free PMC article.
Subclinical cardiovascular disease in patients starting contemporary protease inhibitors.
González-Cordón A, Doménech M, Camafort M, Martínez-Rebollar M, Torres B, Laguno M, Rojas J, Loncà M, Blanco JL, Mallolas J, Gatell JM, de Lazzari E, Martínez E. González-Cordón A, et al. Among authors: rojas j. HIV Med. 2018 May 10. doi: 10.1111/hiv.12619. Online ahead of print. HIV Med. 2018. PMID: 29745457 Free article.
HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe.
Amele S, Sandri AK, Rodger A, Vandekerckhove L, Benfield T, Milinkovic A, Duvivier C, Stellbrink HJ, Sambatakou H, Chkhartishvili N, Caldeira L, Laguno M, Domingo P, Wandeler G, Gisinger M, Kuzovatova E, Dragovic G, Knysz B, Matulionyte R, Rockstroh JK, Lundgren JD, Mocroft A, Peters L; EuroSIDA study group. Amele S, et al. HIV Med. 2022 Jul;23(6):684-692. doi: 10.1111/hiv.13212. Epub 2021 Dec 9. HIV Med. 2022. PMID: 34882940
1,377 results